Today: 30 April 2026
AI stocks slide premarket as Oracle lines up $50 billion raise and Nvidia-OpenAI deal doubts linger

AI stocks slide premarket as Oracle lines up $50 billion raise and Nvidia-OpenAI deal doubts linger

NEW YORK, Feb 2, 2026, 06:17 EST — Premarket

Oracle shares dropped 2.6% in premarket Monday after the company revealed plans to raise $45 billion to $50 billion this year to boost cloud infrastructure for AI workloads. The software giant, led by billionaire Larry Ellison, intends to fund this with roughly equal parts debt and equity, including a new $20 billion at-the-market program that allows gradual share sales. This move aims to support demand from clients like AMD, Meta, Nvidia, OpenAI, TikTok, and xAI. The company has been under pressure following a bondholder lawsuit filed in January and a rise in its credit-default swap costs, a default insurance measure. Russ Mould of AJ Bell noted that Oracle’s fortunes now seem “tied to OpenAI,” while Jefferies analysts cautioned the plan “buys time” but may hurt margins and keep free cash flow in the red until fiscal 2029. Reuters

The AI trade has taken a new turn: it’s increasingly a financing story. Investors are pushing back hard whenever spending outpaces clear signs of returns.

Broader markets wobbled as well. Nasdaq 100 futures dipped roughly 0.9% earlier, pressured by CME Group’s hike in margin requirements on precious-metal contracts. A steep selloff in gold and silver spilled over into stocks, while jitters rose after Donald Trump nominated Kevin Warsh to succeed Jerome Powell at the Federal Reserve. Investors are bracing for a packed week of tech earnings and key U.S. data, including Monday’s manufacturing PMI and Friday’s nonfarm payrolls report.

The Wall Street Journal reported Friday that Nvidia’s effort to invest up to $100 billion in OpenAI has hit a snag, with some insiders at the chipmaker raising doubts. The original deal was non-binding, the report added. Nvidia responded in an emailed statement, saying it has been OpenAI’s “preferred partner” for the past decade and looks forward to ongoing collaboration. Reuters

In Taipei on Saturday, Jensen Huang dismissed claims that Nvidia is growing cold on OpenAI. “We are going to make a huge investment in OpenAI,” he told reporters, also commending OpenAI CEO Sam Altman. Reuters

Other AI-focused megacaps mostly dipped before the open: Nvidia dropped 0.7%, Microsoft lost 0.8%, and Meta slid 2.9%. Alphabet barely moved, Amazon dipped roughly 1%, and AMD took a sharper hit, down 6.1%.

Oracle’s client roster is a who’s who of the AI surge, spanning chip makers to model developers. The real issue now isn’t demand this quarter but just how much financial strain their balance sheets can handle.

That said, the situation works both ways. Should OpenAI’s fundraising stall, or if the data-center expansion loses steam, the stocks might take a quick hit. Rising borrowing costs could also trigger a swift repricing, given how much spending is front-loaded.

Traders eyeing the week ahead will focus on tech earnings for insights into cloud expansion and AI investment, while Friday’s U.S. jobs report on Feb. 6 could shed light on interest rates and risk appetite.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs
Previous Story

Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs

US economic calendar today: ISM factory PMI ahead as S&P 500 futures slip, oil tumbles
Next Story

US economic calendar today: ISM factory PMI ahead as S&P 500 futures slip, oil tumbles

Go toTop